Head-To-Head Analysis: IDEAYA Biosciences (NASDAQ:IDYA) versus Trevi Therapeutics (NASDAQ:TRVI)

IDEAYA Biosciences (NASDAQ:IDYA) and Trevi Therapeutics (NASDAQ:TRVI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership.

Risk and Volatility

IDEAYA Biosciences has a beta of -0.05, meaning that its stock price is 105% less volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500.

Profitability

This table compares IDEAYA Biosciences and Trevi Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
Trevi Therapeutics	N/A	-24.53%	-23.37%

Institutional & Insider Ownership

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by company insiders. Comparatively, 18.3% of Trevi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares IDEAYA Biosciences and Trevi Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71 million	11.64	-$113.70 million	($1.60)	-18.11
Trevi Therapeutics	N/A	N/A	-$42.76 million	($0.32)	-44.41

Trevi Therapeutics has lower revenue, but higher earnings than IDEAYA Biosciences. Trevi Therapeutics is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for IDEAYA Biosciences and Trevi Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1	1	15	0	2.82
Trevi Therapeutics	1	0	9	2	3.00

IDEAYA Biosciences presently has a consensus target price of $50.69, suggesting a potential upside of 74.91%. Trevi Therapeutics has a consensus target price of $22.90, suggesting a potential upside of 61.15%. Given IDEAYA Biosciences’ higher probable upside, analysts clearly believe IDEAYA Biosciences is more favorable than Trevi Therapeutics.

Summary

IDEAYA Biosciences beats Trevi Therapeutics on 7 of the 13 factors compared between the two stocks.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

About Trevi Therapeutics

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.